D Craig Allred

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. pmc Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24
    D Craig Allred
    National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
    J Clin Oncol 30:1268-73. 2012
  2. pmc An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
    Fariba Behbod
    Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
    Breast Cancer Res 11:R66. 2009
  3. doi Ductal carcinoma in situ: terminology, classification, and natural history
    D Craig Allred
    Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8118, St Louis, MO 63110, USA
    J Natl Cancer Inst Monogr 2010:134-8. 2010
  4. doi Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer
    D Craig Allred
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA
    Mod Pathol 23:S52-9. 2010
  5. doi Molecular biomarkers of risk in premalignancy and breast cancer prevention
    D Craig Allred
    Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8118, St Louis, MO 63110, USA
    Cancer Prev Res (Phila) 4:1947-52. 2011
  6. doi The relevance of mouse models to understanding the development and progression of human breast cancer
    D Craig Allred
    Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Mammary Gland Biol Neoplasia 13:279-88. 2008
  7. doi Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution
    D Craig Allred
    Department of Pathology, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Cancer Res 14:370-8. 2008
  8. pmc Alterations of gene expression in the development of early hyperplastic precursors of breast cancer
    Sangjun Lee
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Pathol 171:252-62. 2007
  9. pmc Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer
    Sangjun Lee
    Departments of Pathology and Immunology, Cell Molecular Biology and Physiology, Medicine, BRIGHT Institute, Biostatistics, and Surgery, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer Res 72:4574-86. 2012
  10. pmc Whole-genome analysis informs breast cancer response to aromatase inhibition
    Matthew J Ellis
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA
    Nature 486:353-60. 2012

Detail Information

Publications16

  1. pmc Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24
    D Craig Allred
    National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
    J Clin Oncol 30:1268-73. 2012
    ..Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen...
  2. pmc An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
    Fariba Behbod
    Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
    Breast Cancer Res 11:R66. 2009
    ..The resulting models, which mimicked some of the diversity of human noninvasive breast cancers in vivo, were used to show whether subtypes of human DCIS might contain distinct subpopulations of tumor-initiating cells...
  3. doi Ductal carcinoma in situ: terminology, classification, and natural history
    D Craig Allred
    Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8118, St Louis, MO 63110, USA
    J Natl Cancer Inst Monogr 2010:134-8. 2010
    ..This article provides a general overview of DCIS, including historical perspective, methods of classification, current perspective, and future goals...
  4. doi Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer
    D Craig Allred
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA
    Mod Pathol 23:S52-9. 2010
    ..This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies...
  5. doi Molecular biomarkers of risk in premalignancy and breast cancer prevention
    D Craig Allred
    Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8118, St Louis, MO 63110, USA
    Cancer Prev Res (Phila) 4:1947-52. 2011
    ..Fortunately, there are many other promising biomarkers under investigation, as well as several underutilized experimental strategies which could help promote successful breast cancer prevention...
  6. doi The relevance of mouse models to understanding the development and progression of human breast cancer
    D Craig Allred
    Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Mammary Gland Biol Neoplasia 13:279-88. 2008
    ..This chapter reviews the historical development of mouse models of breast cancer and highlights some of their major strengths, weaknesses, and contributions...
  7. doi Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution
    D Craig Allred
    Department of Pathology, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Cancer Res 14:370-8. 2008
    ..Human invasive breast cancers (IBC) show enormous histologic and biological diversity. This study comprehensively evaluated diversity in ductal carcinoma in situ (DCIS), the immediate precursors of IBCs...
  8. pmc Alterations of gene expression in the development of early hyperplastic precursors of breast cancer
    Sangjun Lee
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Pathol 171:252-62. 2007
    ..Because HELUs are such early potential precursors of breast cancer, targeting some of these alterations may be especially promising strategies for breast cancer prevention...
  9. pmc Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer
    Sangjun Lee
    Departments of Pathology and Immunology, Cell Molecular Biology and Physiology, Medicine, BRIGHT Institute, Biostatistics, and Surgery, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer Res 72:4574-86. 2012
    ..Targeting some of these genes may improve the detection, diagnosis, and therapy of DCIS...
  10. pmc Whole-genome analysis informs breast cancer response to aromatase inhibition
    Matthew J Ellis
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA
    Nature 486:353-60. 2012
    ..Prospective clinical trials based on these findings will require comprehensive genome sequencing...
  11. ncbi Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma
    Jianzhou Wang
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:3107-14. 2002
    ..In this study, the authors investigated the roles of tumor nuclear grade, mitotic activity, and biomarker expression profiles in predicting the pathologic response of breast tumors to preoperative chemotherapy...
  12. doi Pathologic outcomes of nonmalignant papillary breast lesions diagnosed at imaging-guided core needle biopsy
    Susan O Holley
    Breast Imaging Division, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, Campus Box 8131, St Louis, MO 63110, USA
    Radiology 265:379-84. 2012
    ....
  13. ncbi Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays
    Patrick L Fitzgibbons
    Department of Pathology, St Jude Medical Center, Fullerton, California 92835, USA
    Arch Pathol Lab Med 134:930-5. 2010
    ....
  14. pmc Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Matthew J Ellis
    Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Oncol 29:2342-9. 2011
    ..To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations...
  15. ncbi Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma
    Kelly J Butnor
    Department of Pathology, University of Vermont Fletcher Allen Health Care, Burlington, VT 05401, USA
    Arch Pathol Lab Med 130:823-7. 2006
    ..Standard panels of immunohistochemical markers are of limited benefit...